MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors.

Inclusion Criteria:

• Diagnosis of progressive advanced or metastatic (tumor that has spread) solid tumors
• No tumor spread to the brain
• Feeling well other than cancer diagnosis (i.e. lab work, no infection, etc.)
• Available tumor tissue sample from prior surgery
• 4-6 weeks since prior therapy and recovered from prior therapy
• Men and women, ages 18 and above
• Women must not be pregnant or breastfeeding
• Diagnosis of advanced or metastatic (tumor that has spread) colorectal, hepatocellular (liver) or renal (kidney) cancer
• Measurable disease on scans (at least one)